Nine Diagnostics CEO and co-founder Freddy T. Nguyen, MD, PhD has been named a 2025 Scholar in Diagnostic Excellence by the National Academy of Medicine (NAM), one of eleven health professionals selected nationwide through the program’s annual competitive process.
The NAM Scholars in Diagnostic Excellence program is funded by the Gordon and Betty Moore Foundation and operated in partnership with the Council of Medical Specialty Societies (CMSS). It supports mid-career leaders advancing transformative work in diagnostic quality, safety, and equity, and builds on the National Academies’ landmark report Improving Diagnosis in Health Care, which established diagnosis as a critical national priority. Each Scholar receives a research grant and participates in monthly educational sessions, mentorship, and cohort learning activities over a one-year period.
As a Scholar, Nguyen will develop a patient-centered framework for guiding the equitable design and validation of diagnostic technologies. His project, titled “Developing a Patient-Centered Framework to Guide Medical Diagnostic Technology Development,” addresses challenges in bias, validation, study design, data representation, and clinical implementation for next-generation tools. “Diagnostics are the foundation of clinical decision-making, yet diagnostic error remains one of the most significant challenges in medicine,” Nguyen said. “This program is an opportunity to help set a national agenda for how new technologies can improve accuracy, safety, and patient outcomes at scale.”
The recognition reflects Nine Diagnostics’ commitment to ensuring its AI-enabled nanosensor platform is developed against rigorous standards for clinical validity and equitable deployment, advancing not only detection capability but the evidence base required for broad clinical adoption.
About Nine Diagnostics
Nine Diagnostics is an AI-enabled multi-omic nanosensor company advancing precision medicine. The platform simultaneously captures proteomic, metabolomic, and lipidomic signals alongside patient clinical context to generate a multi-omic fingerprint, using machine learning to identify disease-relevant patterns without requiring prior knowledge of which biomarkers matter. This enables pre-treatment patient stratification, on-treatment response monitoring, and post-treatment minimal residual disease detection. Founded by Freddy T. Nguyen, MD, PhD (CEO), Daniel A. Heller, PhD (CSO), and Mijin Kim, PhD (Scientific Advisor), Nine Diagnostics is based in Cambridge, Massachusetts.